Asset Management One
DNLI icon

Asset Management One’s Denali Therapeutics DNLI Stock Holding History

Asset Management One’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$2K – 1017
2022
Q2 		$2K Hold
100
– – ﹤0.01% 1030
2022
Q1 		$3K Hold
100
– – ﹤0.01% 1038
2021
Q4 		$4K Hold
100
– – ﹤0.01% 1048
2021
Q3 		$5K Sell
100
-400
-80% -$22.5K ﹤0.01% 1042
2021
Q2 		$39K Buy
+500
New +$30.9K ﹤0.01% 1031

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Asset Management One's DNLI Position: Q3 2022 in Review

Asset Management One sold out of Denali Therapeutics (DNLI) in Q3 2022, closing a stake of 100 shares — an estimated $2K sold.

Asset Management One first reported a position in DNLI in Q2 2021 and held it in 5 quarters. The position peaked at $39K in Q2 2021. 200 funds tracked by Wall St. Rank hold DNLI as of Q3 2022.

  • Asset Management One reported no remaining Denali Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Asset Management One sold 100 Denali Therapeutics shares in Q3 2022, an estimated $2K.
  • Asset Management One first reported a position in Denali Therapeutics in Q2 2021 and held it in 5 quarters.
  • Asset Management One's Denali Therapeutics position peaked at $39K in Q2 2021.
  • 200 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2022.

Based on Asset Management One's 13F filing for Q3 2022, filed 4 Nov 2022.